WebMD Global requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships with ineligible companies.

Faculty

Philippe Gabriel Steg, MD

Professor of Cardiology
Université Paris-Cité
Chief, Department of Cardiology
Hôpital Bichat, AP-HP
Paris, France

Disclosures

Philippe Gabriel Steg, MD, has the following relevant financial relationships:
Consultant or advisor for: Amarin Corporation plc; AstraZeneca; Bristol Myers Squibb Company; Idorsia Pharmaceuticals, Inc.; Novartis; Sanofi
Speaker or member of speakers bureau for: Amarin Corporation plc; Amgen Inc.; Bristol Myers Squibb Company/MyoKardia; Novo Nordisk
Research funding from: Amarin Corporation plc; AstraZeneca Pharmaceuticals LP; Sanofi
Contracted researcher for: Amarin Corporation plc; AstraZeneca Pharmaceuticals LP; Bayer; Bristol Myers Squibb Company; Idorsia; Novartis; Pfizer, Inc.; Sanofi; SERVIER

Deepak Bhatt, MD, MPH

Dr Valentin Fuster Professor of Cardiovascular Medicine
Icahn School of Medicine at Mount Sinai Health System
Director of Mount Sinai Heart
New York, New York, United States

Disclosures

Deepak Bhatt, MD, MPH, has the following relevant financial relationships:
Consultant or advisor for: Angiowave; Bayer; Boehringer Ingelheim Pharmaceuticals, Inc.; Broadview Ventures; Cardax; CellProthera; Cereno Scientific; High Enroll; Hims, Inc.; Janssen Biotech, Inc.; Level Ex; McKinsey; Merck; MyoKardia; NirvaMed; Novo Nordisk; PhaseBio Pharmaceuticals, Inc.; PLx Pharma; Regado Biosciences; Stasys
Research funding from: Abbott; Acesion Pharma; Afimmune; Aker Biomarine; Amarin Corporation plc; Amgen Inc.; AstraZeneca Pharmaceuticals LP; Bayer; Beren; Boehringer Ingelheim Pharmaceuticals, Inc.; Boston Scientific; Bristol Myers Squibb Company; Cardax; CellProthera; Cereno Scientific; Chiesi; CinCor; Cleerly; CSL Behring; Eisai Inc.; Eli Lilly and Company; Ethicon; Faraday Pharmaceuticals; Ferring Pharmaceuticals; Forest Laboratories; Fractyl; Garmin; HLS Therapeutics; Idorsia Pharmaceuticals, Inc.; Ironwood Pharmaceuticals, Inc.; Ischemix, Inc.; Janssen Biotech, Inc.; Javelin; Lexicon Pharmaceuticals, Inc.; Medtronic, Inc.; Merck; Moderna, Inc.; MyoKardia; NirvaMed; Novartis; Novo Nordisk; Owkin; Pfizer, Inc.; PhaseBio Pharmaceuticals, Inc.; PLx Pharma; Recardio; Regeneron Pharmaceuticals, Inc.; Roche; Sanofi; Stasys; Synaptic; The Medicines Company; Youngene; 89Bio
Contracted researcher for: Abbott; Biotronik; Boston Scientific; CSI; Endotronix; Philips; St. Jude Medical (now Abbott); SpectraWAVE; Svelte; Vascular Solutions
Patent beneficiary of: Sotagliflozin
Stock options from: Angiowave; DRS.LINQ
Owns stock (privately owned) in: High Enroll
Owns stock (publicly traded) in: Bristol Myers Squibb
Other: Board of Directors: Angiowave; Bristol Myers Squibb; DRS.LINQ; High Enroll; TobeSoft
Data Safety Monitoring Committees: Asesion Pharma; Boston Scientific; Contego Medical; Novartis

Lorenz Räber, MD, PhD

Professor of Cardiology
Director of Cardiac Catheter Laboratory
Inselspital, Bern University Hospital
Bern, Switzerland

Disclosures

Lorenz Räber, MD, PhD, has the following relevant financial relationships:
Consultant or advisor for: Abbott; Amgen Inc.; AstraZeneca Pharmaceuticals LP; Canon
Speaker or member of speakers bureau for: Abbott; Medtronic, Inc.; Novo Nordisk; Occlutech; Sanofi
Research funding from: Abbott; Biotronik; Boston Scientific; Regeneron Pharmaceuticals, Inc.; Sanofi

Lale Tokgözoğlu, MD

Professor of Cardiology
Hacettepe University
Ankara, Turkey

Disclosures

Lale Tokgözoğlu, MD, has the following relevant financial relationships:
Consultant or advisor for: Abbott; AstraZeneca Pharmaceuticals LP; Merck Sharp & Dohme; Novartis; Novo Nordisk; Sanofi
Speaker or member of speakers bureau for: Abbott; Amgen Inc.; Bayer; Daiichi Sankyo, Inc.; Novartis; Novo Nordisk; Pfizer, Inc.; Recordati; Sanofi
Research funding from: Amgen Inc.; Novo Nordisk

Editor

Grace O’Malley, BSc, PhD

Associate Medical Education Director, WebMD Global, LLC

Disclosures

Grace O’Malley, BSc, PhD, has no relevant financial relationships

Compliance Reviewer

Amanda Jett, PharmD, BCACP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Amanda Jett, PharmD, BCACP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

CPD

Fine-Tuning Post-Acute Coronary Syndrome Cardioprotection: The Case for Early and Aggressive Lipid Lowering

Authors: Philippe Gabriel Steg, MD; Deepak Bhatt, MD, MPH; Lorenz Räber, MD, PhD; Lale Tokgözoğlu, MD
CPD Released: 9/11/2023
Valid for credit through: 9/11/2024, 11:59 PM EST

Start Activity

Credits Available

Non-US Physicians - maximum of 0.50 CPD

You Are Eligible For
- Letter of Completion

Target Audience and Goal Statement

This activity is intended for an international audience of non-US interventional cardiologists treating patients with ACS.

The goal of this activity is for clinicians to better be able to examine their knowledge regarding the need for early lipid-lowering therapy in patients with post-ACS and the need for early combination lipid-lowering therapy along with practical strategies to ensure seamless handoff of patients with ACS to secondary care.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Latest data on lipid-lowering strategies in the post-ACS period
Have greater competence related to
- Applying practical strategies to ensure seamless handoff of patients with ACS to secondary care
Demonstrate greater confidence in their ability to
- Identify the need for early lipid-lowering therapy in patients post-ACS

Disclosures

Faculty

Philippe Gabriel Steg, MD

Professor of Cardiology
Université Paris-Cité
Chief, Department of Cardiology
Hôpital Bichat, AP-HP
Paris, France

Disclosures

Philippe Gabriel Steg, MD, has the following relevant financial relationships:
Consultant or advisor for: Amarin Corporation plc; AstraZeneca; Bristol Myers Squibb Company; Idorsia Pharmaceuticals, Inc.; Novartis; Sanofi
Speaker or member of speakers bureau for: Amarin Corporation plc; Amgen Inc.; Bristol Myers Squibb Company/MyoKardia; Novo Nordisk
Research funding from: Amarin Corporation plc; AstraZeneca Pharmaceuticals LP; Sanofi
Contracted researcher for: Amarin Corporation plc; AstraZeneca Pharmaceuticals LP; Bayer; Bristol Myers Squibb Company; Idorsia; Novartis; Pfizer, Inc.; Sanofi; SERVIER

Deepak Bhatt, MD, MPH

Dr Valentin Fuster Professor of Cardiovascular Medicine
Icahn School of Medicine at Mount Sinai Health System
Director of Mount Sinai Heart
New York, New York, United States

Disclosures

Deepak Bhatt, MD, MPH, has the following relevant financial relationships:
Consultant or advisor for: Angiowave; Bayer; Boehringer Ingelheim Pharmaceuticals, Inc.; Broadview Ventures; Cardax; CellProthera; Cereno Scientific; High Enroll; Hims, Inc.; Janssen Biotech, Inc.; Level Ex; McKinsey; Merck; MyoKardia; NirvaMed; Novo Nordisk; PhaseBio Pharmaceuticals, Inc.; PLx Pharma; Regado Biosciences; Stasys
Research funding from: Abbott; Acesion Pharma; Afimmune; Aker Biomarine; Amarin Corporation plc; Amgen Inc.; AstraZeneca Pharmaceuticals LP; Bayer; Beren; Boehringer Ingelheim Pharmaceuticals, Inc.; Boston Scientific; Bristol Myers Squibb Company; Cardax; CellProthera; Cereno Scientific; Chiesi; CinCor; Cleerly; CSL Behring; Eisai Inc.; Eli Lilly and Company; Ethicon; Faraday Pharmaceuticals; Ferring Pharmaceuticals; Forest Laboratories; Fractyl; Garmin; HLS Therapeutics; Idorsia Pharmaceuticals, Inc.; Ironwood Pharmaceuticals, Inc.; Ischemix, Inc.; Janssen Biotech, Inc.; Javelin; Lexicon Pharmaceuticals, Inc.; Medtronic, Inc.; Merck; Moderna, Inc.; MyoKardia; NirvaMed; Novartis; Novo Nordisk; Owkin; Pfizer, Inc.; PhaseBio Pharmaceuticals, Inc.; PLx Pharma; Recardio; Regeneron Pharmaceuticals, Inc.; Roche; Sanofi; Stasys; Synaptic; The Medicines Company; Youngene; 89Bio
Contracted researcher for: Abbott; Biotronik; Boston Scientific; CSI; Endotronix; Philips; St. Jude Medical (now Abbott); SpectraWAVE; Svelte; Vascular Solutions
Patent beneficiary of: Sotagliflozin
Stock options from: Angiowave; DRS.LINQ
Owns stock (privately owned) in: High Enroll
Owns stock (publicly traded) in: Bristol Myers Squibb
Other: Board of Directors: Angiowave; Bristol Myers Squibb; DRS.LINQ; High Enroll; TobeSoft
Data Safety Monitoring Committees: Asesion Pharma; Boston Scientific; Contego Medical; Novartis

Lorenz Räber, MD, PhD

Professor of Cardiology
Director of Cardiac Catheter Laboratory
Inselspital, Bern University Hospital
Bern, Switzerland

Disclosures

Lorenz Räber, MD, PhD, has the following relevant financial relationships:
Consultant or advisor for: Abbott; Amgen Inc.; AstraZeneca Pharmaceuticals LP; Canon
Speaker or member of speakers bureau for: Abbott; Medtronic, Inc.; Novo Nordisk; Occlutech; Sanofi
Research funding from: Abbott; Biotronik; Boston Scientific; Regeneron Pharmaceuticals, Inc.; Sanofi

Lale Tokgözoğlu, MD

Professor of Cardiology
Hacettepe University
Ankara, Turkey

Disclosures

Lale Tokgözoğlu, MD, has the following relevant financial relationships:
Consultant or advisor for: Abbott; AstraZeneca Pharmaceuticals LP; Merck Sharp & Dohme; Novartis; Novo Nordisk; Sanofi
Speaker or member of speakers bureau for: Abbott; Amgen Inc.; Bayer; Daiichi Sankyo, Inc.; Novartis; Novo Nordisk; Pfizer, Inc.; Recordati; Sanofi
Research funding from: Amgen Inc.; Novo Nordisk

Editor

Grace O’Malley, BSc, PhD

Associate Medical Education Director, WebMD Global, LLC

Disclosures

Grace O’Malley, BSc, PhD, has no relevant financial relationships

Compliance Reviewer

Amanda Jett, PharmD, BCACP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Amanda Jett, PharmD, BCACP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements

For Physicians

The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.50 continuing professional development credits (CPD).

Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

From Medscape Education

CPD

Fine-Tuning Post-Acute Coronary Syndrome Cardioprotection: The Case for Early and Aggressive Lipid Lowering

Authors: Philippe Gabriel Steg, MD; Deepak Bhatt, MD, MPH; Lorenz Räber, MD, PhD; Lale Tokgözoğlu, MDFaculty and Disclosures

CPD Released: 9/11/2023

Valid for credit through: 9/11/2024, 11:59 PM EST

processing....

Educational Impact Challenge

Please answer the questions below to self-assess your knowledge. Answering these questions again after the activity will allow you to see what you learned.

Page 1 of 4

CPD Information Download Slides

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred.

The material presented here does not necessarily reflect the views of WebMD, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been authorized by the European Medicines Agency for use in Europe, off-label uses of authorized products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

Faculty and Disclosures

Faculty

Philippe Gabriel Steg, MD

Deepak Bhatt, MD, MPH

Lorenz Räber, MD, PhD

Lale Tokgözoğlu, MD

Editor

Grace O’Malley, BSc, PhD

Compliance Reviewer

Amanda Jett, PharmD, BCACP

Peer Reviewer

CPD

Fine-Tuning Post-Acute Coronary Syndrome Cardioprotection: The Case for Early and Aggressive Lipid Lowering

Credits Available

You Are Eligible For

Target Audience and Goal Statement

Disclosures

Faculty

Philippe Gabriel Steg, MD

Deepak Bhatt, MD, MPH

Lorenz Räber, MD, PhD

Lale Tokgözoğlu, MD

Editor

Grace O’Malley, BSc, PhD

Compliance Reviewer

Amanda Jett, PharmD, BCACP

Peer Reviewer

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Fine-Tuning Post-Acute Coronary Syndrome Cardioprotection: The Case for Early and Aggressive Lipid Lowering

Educational Impact Challenge